TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22289674
Drug: H2-receptor antagonists
Normalized name: H2-receptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-receptor antagonists (H2RA) administered per os as a single dose immediately before surgery
Study: 22289674
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitors (PPI) administered in two oral doses (the night before and on the morning of surgery)
Study: 22289674
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitors (PPI) administered as a single intravenous infusion
Study: 22289674
Drug: H2-receptor antagonists
Normalized name: H2-receptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-receptor antagonists (H2RA) administered in two doses (the night before and on the morning of surgery)
Study: 20809746
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of implant type, preoperative knee joint loading patterns during gait, and body mass index
Study: 12874608
Drug: Valsartan in
Normalized name: Product containing valsartan in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan in combination with hydrochlorothiazide (n=276)
Study: 12874608
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (Control group, n=27)
Study: 10984366
Drug: Oxitropium bromide
Normalized name: oxitropium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxitropium bromide (100 microg/actuation) plus salbutamol (100 microg/actuation) administered as 4 puffs every 20 minutes for 3 doses.
Study: 10984366
Drug: Salbutamol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (100 microg/actuation) alone administered as 4 puffs every 20 minutes for 3 doses.
Study: 8560674
Drug: Bicalutamide 50
Normalized name: bicalutamide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide 50 mg/day for 12 weeks
Study: 8560674
Drug: Bicalutamide 100-200
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicalutamide 100-200 mg/day
Study: 8560674
Drug: Bicalutamide up
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicalutamide up to 450 mg daily
Study: 1832346
Drug: Dianette +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dianette + 2 mg CPA
Study: 1832346
Drug: Dianette +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dianette + 20 mg CPA
Study: 1832346
Drug: Dianette +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dianette + 100 mg CPA
Study: 30617197
Drug: obinutuzumab plus
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, prednisone chemotherapy
Study: 30239561
Drug: 3-hydroxybutyrate (3OHB)
Normalized name: 2-Amino-3-hydroxybutyric acid
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-hydroxybutyrate (3OHB) infusion
Study: 30239561
Drug: Nonesterified fatty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonesterified fatty acids (Intralipid) infusion
Study: 26991329
Drug: 30-min plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-min plasma glucose (30-min PG) tertiles: T1 < 9.1 mmol/L, T2 9.2-10.4 mmol/L, T3 ≥ 10.4 mmol/L
Study: 24913484
Drug: Energy drink
Normalized name: Boost Energy Drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy drink (500 ml containing 160 mg of caffeine)
Study: 24913484
Drug: Energy drink
Normalized name: Boost Energy Drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy drink + Rest (500 ml of energy drink and 10 min rest after 100 min of driving)
Study: 24913484
Drug: Placebo drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drink (500 ml)
Study: 11880561
Drug: Oat consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat consumption (14 g/d of dietary fiber, 5.5 g beta-glucan)
Study: 11880561
Drug: Wheat cereals
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat cereals (14 g/d of dietary fiber, no beta-glucan)
Study: 8566890
Drug: Single-donor fresh
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-donor fresh frozen plasma (FFP) substitution, total of 42 doses at a median of 10 (5-20) mliter/kg.
Study: 2278982
Drug: Inpatient family
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient family intervention (IFI) added to medication during the inpatient phase of treatment.
Study: 7193668
Drug: Intravenous Dalacin
Normalized name: Dalacin T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Dalacin C and Spectacilline for five days postoperatively
Study: 7193668
Drug: Taurolin administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurolin administered by intraperitoneal route
Study: 31792863
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group received normal care plus HCV antibody tests ordered and customized messages sent through their tPHR inviting them to go directly to the lab for HCV screening over a 12-week period.
Study: 15936996
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of pravastatin daily
Study: 31190609
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment (both atorvastatin and pravastatin)
Study: 23979564
Drug: Class III
Normalized name: HLA class III antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class III anti‐arrhythmic drugs at baseline
Study: 23979564
Drug: Oral anti‐coagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anti‐coagulation (OAC) without anti‐platelet drugs
Study: 23979564
Drug: Drug conversions
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug conversions
Study: 21131556
Drug: BMS-641988 (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-641988 (daily doses escalated from 5 to 150 mg)
Study: 15588464
Drug: Cetrorelix 3
Normalized name: cetrorelix 3 mg subcutaneous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrorelix 3 mg on stimulation day 7 with r-hLH 150 IU on days 7-10 (n = 25)
Study: 15588464
Drug: Cetrorelix 3
Normalized name: cetrorelix 3 mg subcutaneous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrorelix 3 mg on stimulation day 7 without r-hLH on days 7-10 (n = 24)
Study: 31998847
Drug: Aspirin withdrawal
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin withdrawal
Study: 22425883
Drug: Naproxcinod, Naproxen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxcinod, Naproxen, Ibuprofen
Study: 28073964
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg tenofovir disoproxil fumarate/400 mg emtricitabine
Study: 18309452
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg hydrocortisone (HC) replacement therapy on the day of surgery, tapered off thereafter
Study: 18309452
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg hydrocortisone (HC) replacement therapy
Study: 16540883
Drug: Famciclovir 250
Normalized name: famciclovir 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir 250 mg bid for 16 weeks
Study: 16540883
Drug: Valacyclovir 500
Normalized name: valacyclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 500 mg qd for 16 weeks
Study: 16540883
Drug: Famciclovir 250
Normalized name: famciclovir 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir 250 mg bid for 10 weeks
Study: 16540883
Drug: Valacyclovir 500
Normalized name: valacyclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 500 mg qd for 10 weeks
Study: 10090428
Drug: Clarithromycin 250
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 250 mg twice daily for 10 days
Study: 23934773
Drug: low-fat, high-complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: low-fat, high-complex carbohydrate diet supplemented with 1.24 g/day of long-chain n-3 PUFA
Study: 16231256
Drug: Other Licensed
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other Licensed Antifungal Therapies (OLAT) after amphotericin B deoxycholate
Study: 16231256
Drug: Salvage therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage therapy with lipid formulation of amphotericin B after initial treatment with amphotericin B deoxycholate
Study: 17342994
Drug: Reinhartdt and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinhartdt and sea cucumber capsule (RSC) combined with Donepezil
Study: 17342994
Drug: Reinhartdt and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinhartdt and sea cucumber capsule (RSC)
Study: 11673815
Drug: Ritonavir 200
Normalized name: lopinavir-ritonavir 200 mg-50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir 200 mg bid + saquinavir 600 mg bid (Rito-Saq)
Study: 11673815
Drug: Nelfinavir 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir 1,000 mg bid + saquinavir 600 mg bid (Nelf-Saq)
Study: 3197710
Drug: FDDF oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDDF oral administration of lorazepam 4 mg
Study: 3197710
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of lorazepam 4 mg
Study: 18579216
Drug: Quetiapine (400-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (400-800 mg/day) plus lithium/divalproex
Study: 12885680
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg enoxaparin sodium
Study: 12885680
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg enoxaparin
Study: 12885680
Drug: Oral tenoxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tenoxicam
Study: 10558945
Drug: Ciprofloxacin (single-dose)
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin (single-dose)
Study: 8914204
Drug: Tamoxifen in
Normalized name: Product containing tamoxifen in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen in combination with chemotherapy for metastatic melanoma
Study: 8914204
Drug: Steroid hormones
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Steroid hormones
Study: 1677820
Drug: Pipecuronium (PIP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipecuronium (PIP), 0.10 mg/kg
Study: 1677820
Drug: Vecuronium (V),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (V), 0.12 mg/kg
Study: 30448030
Drug: TURBT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TURBT plus immediate postoperative epirubicin (50 mg)
Study: 28070882
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 180 mg ticagrelor pre-PCI, followed by ticagrelor 90 mg twice daily post-PCI (group TT)
Study: 28070882
Drug: Maintenance dose
Normalized name: Firmagon 80mg Powder for Injection Maintenance Dose Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance dose of ticagrelor 90 mg twice daily (group CT)
Study: 28070882
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg daily post-PCI (group CC)
Study: 28070882
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of ticagrelor (group TT)
Study: 25606328
Drug: Low Level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Level Laser Therapy (LLLT) and splinting
Study: 31662030
Drug: Chemotherapy or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy or surgery only (based on model recommendation)
Study: 30646158
Drug: Late parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late parenteral nutrition (PN) initiated after 1 week
Study: 30646158
Drug: Early parenteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early parenteral nutrition (PN) initiated within 24 hours
Study: 12925054
Drug: Motivational and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational and solution-focused therapy group intervention
Study: 9082675
Drug: Tedisamil 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tedisamil 0.3 mg/kg BW
Study: 9082675
Drug: Tedisamil 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tedisamil 0.4 mg/kg BW
Study: 7423284
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 tablets administered intravaginally
Study: 31778436
Drug: High-intensity laser
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity laser therapy at 1064 nm and 60 J/cm2 for 10 min (HILT)
Study: 31778436
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy at 785 nm and 8 J/cm2 for 8 min (LLLT)
Study: 28179223
Drug: Whole grain-rich
Normalized name: rice (whole grain) allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole grain-rich diet (207 ± 39 g whole grains plus 40 ± 5 g dietary fiber/d)
Study: 28179223
Drug: Refined grain-based
Normalized name: barley grain
DrugBank: Barley (DB10506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refined grain-based diet (0 g whole grains plus 21 ± 3 g dietary fiber/d)
Study: 25894405
Drug: Probiotics (Lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Lactobacillus acidophilus, L. plantarum, Bifidobacterium lactis, Saccharomyces boulardii)
Study: 12729938
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of sustained‐release melatonin
Study: 9917048
Drug: 4% cocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% cocaine solution for 10 min (160 mg)
Study: 9917048
Drug: 4% cocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% cocaine solution for 20 min (160 mg)
Study: 9917048
Drug: 10% cocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% cocaine solution for 20 min (400 mg)
Study: 2186909
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily netilmicin (n = 98)
Study: 2186909
Drug: Thrice daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice daily netilmicin (n = 99)
Study: 30729945
Drug: Laser‐activated irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser‐activated irrigation (LAI) with no solution
Study: 28467859
Drug: Bambuterol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bambuterol (20 mg)
Study: 28467859
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of theophylline and bambuterol
Study: 23938173
Drug: Modafinil (50-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (50-200 mg/day)
Study: 16634542
Drug: Org 9426
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 9426 0.3 mg x kg(‐1)
Study: 16634542
Drug: Org 9426
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 9426 0.6 mg x kg(‐1)
Study: 16634542
Drug: Org 9426
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 9426 0.9 mg x kg(‐1)
Study: 12738151
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 400 micro g, followed by two doses of oral misoprostol 100 micro g 4 hours apart (Group 2)
Study: 12738151
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of oxytocin 10 IU plus oral misoprostol 400 micro g, followed by two doses of oral misoprostol 100 micro g 4 hours apart (Group 1)
Study: 12738151
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of oxytocin 10 IU plus intramuscular administration of methylergonovine maleate 0.2 mg (Group 4)
Study: 8857441
Drug: Dopexamine infusion
Normalized name: dopexamine
DrugBank: Dopexamine (DB12313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopexamine infusion at a dose of 2 microg kg-1 min-1, titrated to achieve normal blood pressure, urine output, and base deficit.
Study: 1507375
Drug: Aspirin (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (two 325‐mg tablets once per day)
Study: 31432311
Drug: Sodium hypochlorite
Normalized name: Sodium hypochlorite
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium hypochlorite gel
Study: 28259320
Drug: Amoxicillin 500
Normalized name: amoxicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 500 MG plus Metronidazole 500 MG 3 times a day for 3 or 7 days
Study: 27006286
Drug: Midazolam (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (low dose)
Study: 24927970
Drug: Trimetazidine (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (70 mg/day for 72 hours)
Study: 19071066
Drug: Standard diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard diet and behavioral therapy (stimulation off)
Study: 17214729
Drug: Allylamine-benzoyl peroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allylamine-benzoyl peroxide combination therapy
Study: 17214729
Drug: Proactiv Solution
Normalized name: Proactiv Solution Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactiv Solution (benzoyl peroxide alone)
Study: 9231212
Drug: artemisinin suppositories
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: artemisinin suppositories followed by mefloquine
Study: 9231212
Drug: intramuscular artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: intramuscular artesunate followed by mefloquine
Study: 9231212
Drug: intravenous quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous quinine followed by pyrimethamine/sulfadoxine
Study: 8094279
Drug: Weekly alternating
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly alternating zidovudine (200 mg every 4 hours) and ddC (0.03 mg/kg every 4 hours)
Study: 8094279
Drug: Weekly intermittent
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly intermittent zidovudine (200 mg every 4 hours)
Study: 8094279
Drug: Continuous zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous zidovudine therapy
Study: 8094279
Drug: Alternating therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating therapy with zidovudine and ddC
Study: 8094279
Drug: Alternating therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating therapy limbs
Study: 7496696
Drug: Iodixanol 270
Normalized name: IODIXANOL 270mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodixanol 270 mgI ml‐1
Study: 7496696
Drug: Iopamidol 300
Normalized name: iopamidol 300 mg iodine/mL (61 %) INTRAVEN KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopamidol 300 mgI ml‐1
Study: 1675534
Drug: Topical meclocycline
Normalized name: meclocycline Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical meclocycline sulfosalicylate
Study: 1675534
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (topical meclocycline sulfosalicylate and benzoyl peroxide)
Study: 31412895
Drug: Standard TB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard TB therapy (for HIV-positive patients)
Study: 31412895
Drug: Standard TB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard TB therapy (for HIV-negative patients)
Study: 31412895
Drug: Standard TB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard TB therapy (for both groups)
Study: 22463733
Drug: Directed home
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directed home medicines review service
Study: 20049950
Drug: pH-dependent release
Normalized name: PH-284
DrugBank: PH-284 (DB05452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH-dependent release formulation 3.6 g/day
Study: 20049950
Drug: pH-dependent release
Normalized name: PH-284
DrugBank: PH-284 (DB05452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH-dependent release formulation 2.4 g/day
Study: 20049950
Drug: Time-dependent release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-dependent release formulation 2.25 g/day
Study: 20049950
Drug: pH-dependent release
Normalized name: PH-284
DrugBank: PH-284 (DB05452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH-dependent release formulations (2.4 g and 3.6 g)
Study: 18411384
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin therapy using glargine self-titrated according to a patient algorithm
Study: 18411384
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy with physician-adjusted doses of oral agents
Study: 397711
Drug: Nefopam 15
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam 15 mg (maximum 90 mg)
Study: 397711
Drug: Oxycodone 4
Normalized name: OXYCODONE 4.88MG/ASA 325MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 4 mg (maximum 24 mg)
Study: 6287928
Drug: Intranasal enviroxime
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal enviroxime (one spray per nostril, five times per day)
Study: 6287928
Drug: Intranasal enviroxime
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal enviroxime
Study: 31237727
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg risankizumab
Study: 26171754
Drug: Video consultation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Video consultation during monthly home visits